---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-067071"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:19:50.643254+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tenaya Therapeutics approves restructuring; workforce reduction extends cash runway to H2 2026

## Summary
- Restructuring focuses resources on TN-201 (MyPEAK-1) and TN-401 (RIDGE-1) gene therapy trials.
- Workforce reduction implemented; no expected impact on enrollment milestones or data readouts.
- Estimated severance and health benefit charges of $1.6M–$2.7M, substantially all by Q3 2025.
- Cash runway extended into second half of 2026 via cost-containment measures.
- Sufficient drug product produced for ongoing trials; manufacturing for pivotal studies continues.

## SEC filing metadata
- accession: 0001193125-25-067071
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000119312525067071/0001193125-25-067071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000119312525067071/d660778d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-067071
- JSON: https://secwatch.observer/filing/0001193125-25-067071.json
- Plain text: https://secwatch.observer/filing/0001193125-25-067071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.